{
  "_id": "e646831f42a49f0fb29ccddbf888b4af923937db052acb72c1e413b05dd15414",
  "feed": "market-watch",
  "title": "Market rout casts cloud over biggest IPO of the year as at least two deals are pulled during brutal selloff; AIG unit Corebridge Financial is expected to price its IPO later Wednesday but may have to settle for low end of range",
  "text": "<p>And cancer-focused biotech Elicio Therapeutics pulled its $40 million offering, according to Renaissance.</p><p>The decisions came as the Dow Jones Industrial Average shed 1,300 points to mark itsworst one-day performance since June 11 of 2020,following an unexpectedly hot consumer-price inflation reading for August.</p><p>The S&amp;P 500 shed 4.3%, while the Nasdaq Composite COMP fell 5.2% in a broad-based selloff. All 11 S&amp;P 500 sectors finished in the red after the August consumer-price index, or CPI, rose 0.1% in August. Though the year-over-year rate slowed to 8.3% from 8.5% in July, economists had been looking for a monthly fall of 0.1% that would bring the year-over-year rate down to 8%.</p><p>Corebridge is still expected to price its deal later Wednesday, according to IPOScoop.com,although there are concerns it may come at the low end of its range of $21 to $24 a share. Corebridge is planning to offer 80 million shares to raise the most of any deal in this year's frozen market.</p><p>In a sign of just how think the market has been, the deal, if completed as planned, would account for more than a quarter of this year's overall proceeds.</p><p>For more, see:  This AIG spinoff is the biggest IPO of the year at just $1.8 billion in a sign of the deep freeze in new offerings</p><p>To be sure, Corebridge has some points in its favor, not least being that it's profitable and has delivered solid growth. Corebridge had net income of $6.4 billion in the first half of the year on revenue of $16 billion, according to its filing documents. That was up from net income of $2.8 billion in the year-earlier period, on revenue of $11.02 billion.</p><p>The company is planning to pay quarterly dividends, offering a 4.1% annualized yield at the midpoint of its range, according to Renaissance co-Founder and CEO Bill Smith. It had $358 billion in client assets as of June 30.</p><p>The deal has a strong roster of underwriters at 43 banks, with JPMorgan acting as lead.</p><p>Linkbancorp Inc. LNKB, which operates Pennsylvania-based The Gratz Bank, priced its public offering on Tuesday at $7.50 a share, below its price range of $8.00 to $9.50. That offering was an uplisting to the Nasdaq from the OTC market. The stock was up 2.4% in recent trades.</p><p>Also on the docket Wednesday is biotech Third Harmonic Bio. THRD The company specializes in treatments for allergic and inflammatory diseases and plans to offer 9 million shares priced at $16 to $18 each.</p><p>The Renaissance IPO ETF IPO was up 1.3% Wednesday, but has fallen 43% in the year to date, while the S&amp;P 500 SPX has fallen 17%.</p><p>Read now: You bought. They sold. Meet some of the insiders who unloaded $35 billion in stock amid the tech IPO bonanza before it tanked.</p><p>Market rout casts cloud over biggest IPO of the year as at least two deals are pulled during brutal selloff</p>",
  "published": "2022-09-14T18:12:00.000Z",
  "tags": [
    {
      "id": "US46625H1005",
      "name": "JPMorgan Chase & Co.",
      "offsets": [
        {
          "start": 1908,
          "end": 1916
        }
      ],
      "nexusId": "10009914"
    }
  ]
}